Jun 13, 2020
EHA25Virtual: A Paradigm Shift for the Treatment of Newly Diagnosed Older Acute Myeloid Leukemia Patients
Jun 12, 2020
Tolero Pharmaceuticals Presents Findings from Phase 1 Zella 101 Clinical Study Evaluating Investigational Agent Alvocidib in Patients with Newly Diagnosed Acute Myeloid Leukemia at Virtual EHA Annual Congress 2020
May 14, 2020
Jazz Pharmaceuticals to Showcase New Data From its Growing Oncology Portfolio at Virtual ASCO and EHA 2020 Meetings
May 14, 2020
25th EHA Congress: Menarini Ricerche Discloses First Results From the Clinical Study on SEL24/MEN1703
Apr 28, 2020
Cardioprotective Drug Prevents Severe Cardiac Events in Children Undergoing Chemotherapy for Acute Myeloid Leukemia
Apr 28, 2020
Moleculin Approved to Accelerate European Clinical Trial
Feb 28, 2020
AbbVie Provides Update from Phase 3 Study Evaluating VENCLEXTA® (venetoclax) in Combination with Low-Dose Cytarabine in Newly-Diagnosed Patients with Acute Myeloid Leukemia (AML)
Feb 28, 2020
AbbVie Provides Update from Phase 3 Study Evaluating VENCLEXTA® (venetoclax) in Combination with Low-Dose Cytarabine in Newly-Diagnosed Patients with Acute Myeloid Leukemia (AML)
Feb 26, 2020
Actinium Announces Actimab-A Plus 7+3 Combination Trial for Newly Diagnosed Acute Myeloid Leukemia Patients
Feb 03, 2020
Moleculin Announces Successful Completion of US Phase 1 AML Trial of Annamycin
Jan 15, 2020
Tolero Pharmaceuticals Announces First Patient Dosed in Phase 2 Zella 202 Study of Investigational Agent Alvocidib in Patients with Relapsed or Refractory Acute Myeloid Leukemia Following Treatment with Venetoclax and HMA Combination Therapy
Jan 14, 2020
Health Canada Approves Astellas' XOSPATA® (gilteritinib) for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation
Jan 06, 2020
Precigen Receives FDA Orphan Drug Designation for PRGN-3006 UltraCAR-T(TM) in Patients with Acute Myeloid Leukemia (AML)
Dec 09, 2019
BerGenBio Presents Preliminary Clinical Data From Phase II Combination Trial of Bemcentinib and LDAC in Elderly AML Patients at ASH 2019
Dec 06, 2019
Denovo Biopharma Licenses Global Rights to a Novel Late-Stage Oncology Drug from Sunesis Pharmaceuticals
Dec 04, 2019
Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia
Dec 04, 2019
Biotechs Move Forward Developing Latest Targeted Therapies for Acute Myeloid Leukemia
Nov 19, 2019
Biosight Announces Data to be Presented at ASH 2019 Annual Meeting
Nov 07, 2019
Jazz Pharmaceuticals to Highlight Growing Hematology Oncology Pipeline at ASH 2019 Annual Meeting
Oct 30, 2019
European Commission Approves Astellas' XOSPATA(TM) for Patients with Relapsed or Refractory Acute Myeloid Leukemia with Mutations Detected using Invivoscribe's LeukoStrat® CDx FLT3 Mutation Assay